

Updates in the Diagnosis and Management of CKD: The Role of Mineralocorticoid Antagonists in Evolving the Therapeutic Landscape - Case Review #1

References

Post 6

Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis & management: a review. *JAMA*. 2019;322(13):1294-1304. doi:10.1001/jama.2019.14745

What is the difference between sCr, eGFR, ACR, & BUN? National Kidney Foundation. March 2, 2018. Accessed May 2021. <https://www.kidney.org/newsletter/what-difference-between-scr-egfr-acr-and-bun>

Post 7

What is the difference between sCr, eGFR, ACR, & BUN? National Kidney Foundation. March 2, 2018. Accessed May 2021. <https://www.kidney.org/newsletter/what-difference-between-scr-egfr-acr-and-bun>

Post 8

Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis & management: a review. *JAMA*. 2019;322(13):1294-1304. doi:10.1001/jama.2019.14745

Post 9

Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis & management: a review. *JAMA*. 2019;322(13):1294-1304. doi:10.1001/jama.2019.14745

Post 11

Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation & mineralocorticoid receptor antagonist treatment in cardiac & renal diseases. *Hypertension*. 2015;65(2):257-263. doi:10.1161/HYPERTENSIONAHA.114.04488

Epstein M. Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism. *Lancet Diabetes Endocrinol*. 2015;3(12):993-1003. doi:10.1016/S2213-8587(15)00289-2

Post 12

Epstein M. Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism. *Lancet Diabetes Endocrinol.* 2015;3(12):993-1003. doi:10.1016/S2213-8587(15)00289-2

Post 13

Epstein M. Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism. *Lancet Diabetes Endocrinol.* 2015;3(12):993-1003. doi:10.1016/S2213-8587(15)00289-2

Post 15

Bayer's finerenone meets primary endpoint in Phase III FIDELIO-DKD renal outcomes study in patients with chronic kidney disease and Type 2 diabetes. BusinessWire. July 9, 2020.
<https://www.businesswire.com/news/home/20200709005224/en/Bayer's-Finerenone-Meets-Primary-Endpoint-Phase-III>. Published 2020

Post 16

Kolkhof P, Jaisser F, Kim SY, Filippatos G, Nowack C, Pitt B. Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. *Handb Exp Pharmacol.* 2017;243:271-305. doi: 10.1007/164_2016_76

Post 19

Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis & management: a review. *JAMA.* 2019;322(13):1294-1304. doi:10.1001/jama.2019.14745

Glossary

A2-4, albuminuria categories

ACR, albumin-to-creatinine ratio

BUN, blood urea nitrogen

CGA, cause, eGFR, and ACR

CKD, chronic kidney disease

COX-2, cyclooxygenase-2

CV, cardiovascular

eGFR, estimated glomerular filtration rate

FDA, Food & Drug Administration

G2,3a,4,5, eGFR categories

HF, heart failure

HTN, hypertension

ID, identification

Mos, months

MR, mineralocorticoid receptor

NKF, National Kidney Foundation

PAI-1, plasminogen activator inhibitor-1

Pt, patient

ROS, reactive oxygen species

T2DM, type two diabetes mellitus

TGF β ₁, transforming growth factor beta 1

Tx, treatment

w/, with

Yo, years old

yr, year